Ubs Group Ag Sab Biotherapeutics, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.62 - $1.0 $310 - $500	500 New	500 $0
Q1 2023 May 12, 2023	SELL	$0.42 - $0.75 $104 - $186	-248 Reduced 3.58%	6,679 $2,000
Q4 2022 Feb 08, 2023	BUY	$0.54 - $9.8 $2,928 - $53,145	5,423 Added 360.57%	6,927 $4,000
Q3 2022 Nov 10, 2022	BUY	$0.13 - $12.4 $65 - $6,249	504 Added 50.4%	1,504 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.11 - $3.46 $451 - $1,408	-407 Reduced 28.93%	1,000 $1,000
Q1 2022 May 16, 2022	SELL	$1.78 - $8.5 $8,091 - $38,641	-4,546 Reduced 76.36%	1,407 $6,000
Q4 2021 Feb 14, 2022	BUY	$7.3 - $11.24 $43,456 - $66,911	5,953 New	5,953 $47,000

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $111M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.